Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,360

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

Open access
Planchard, David, Smit, Egbert F, Groen, Harry J M, Mazieres, Julien, Besse, Benjamin, Helland, Åslaug, Giannone, Vanessa, D'Amelio, Anthony M, Zhang, Pingkuan, Mookerjee, Bijoyesh, Johnson, Bruce E·2017·The Lancet Oncology
DOI 10.1016/s1470-2045(17)30679-4
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(17)30679-4

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 18

  1. Barlesi, 2016, Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet, 387, 1415, 10.1016/S0140-6736(16)00004-0 · DOI · Paper page
  2. Paik, 2011, Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations, J Clin Oncol, 29, 2046, 10.1200/JCO.2010.33.1280 · DOI · Paper page
  3. Cardarella, 2013, Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer, Clin Cancer Res, 19, 4532, 10.1158/1078-0432.CCR-13-0657 · DOI · Paper page
  4. Marchetti, 2011, Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations, J Clin Oncol, 29, 3574, 10.1200/JCO.2011.35.9638 · DOI · Paper page
  5. Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774 · DOI · Paper page
  6. Planchard, 2016, Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open label, multicentre phase 2 trial, Lancet Oncol, 17, 984, 10.1016/S1470-2045(16)30146-2 · DOI · Paper page
  7. Planchard, 2017, Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study, Proc Am Soc Clin Oncol, 35
  8. Long, 2015, Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, Lancet, 386, 444, 10.1016/S0140-6736(15)60898-4 · DOI · Paper page
  9. Robert, 2015, Improved overall survival in melanoma with combined dabrafenib and trametinib, N Engl J Med, 372, 30, 10.1056/NEJMoa1412690 · DOI · Paper page
  10. Noeparast, 2016, Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of trametinib and dabrafenib, Oncotarget
  11. Venur, 2016, Targeted therapy in brain metastases: ready for primetime?, Am Soc Clin Oncol Educ Book, 35, e123, 10.1200/EDBK_100006 · DOI
  12. Davies, 2017, Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial, Lancet Oncol, 18, 863, 10.1016/S1470-2045(17)30429-1 · DOI · Paper page
  13. Hellmann, 2017, Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study, Lancet Oncol, 18, 31, 10.1016/S1470-2045(16)30624-6 · DOI · Paper page
  14. Sabari, 2017, PD-L1 expression and response to immunotherapy in patients with MET exon 14-alterated non-small cell lung cancers (NSCLC), Proc Am Soc Clin Oncol, 35
  15. Gainor, 2016, EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis, Clin Cancer Res, 22, 4585, 10.1158/1078-0432.CCR-15-3101 · DOI · Paper page
  16. Spagnolo, 2015, BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies, Onco Targets Ther, 8, 157, 10.2147/OTT.S39096 · DOI · Paper page
  17. Lin, 2014, Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer, Proc Natl Acad Sci USA, 111, E748, 10.1073/pnas.1320956111 · DOI
  18. Sen, 2012, Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib, Sci Transl Med, 4, 136ra70, 10.1126/scitranslmed.3003513 · DOI

Cited by

See all 1,360

Metadata

Authors
Planchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, Å., Giannone, V., D'Amelio, A. M., Zhang, P., Mookerjee, B., & Johnson, B. E.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2017-10
Volume
18
Issue
10
Pages
1307-1316
ISSN
1470-2045 (ISSN-L)
DOI
10.1016/s1470-2045(17)30679-4
OpenAlex
W2409383155
Cited by
1,360
References
21
FWCI
111.57
Type
journal article
Language
en
Open access
bronze
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • GlaxoSmithKline
  • Novartis Pharmaceuticals Corporation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(17)30679-4
The paper
Planchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, Å., Giannone, V., D'Amelio, A. M., Zhang, P., Mookerjee, B., & Johnson, B. E. (2017). Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(17)30679-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.